1. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol. 2007;157:1103-1115.
2. Menter MA. An overview of psoriasis. In: Koo JYM, Levin EC, Leon A, et al, eds. Moderate to Severe Psoriasis . 4th ed. Boca Raton, FL: CRC Press Taylor & Francis Group; 2014:1-21.
3. Sandoval LF, Feldman SR. General approach to psoriasis treatment. In: Koo JYM, Levin EC, Leon A, et al, eds. Moderate to Severe Psoriasis . 4th ed. Boca Raton, FL: CRC Press Taylor & Francis Group; 2014:3-8.
4. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010;(3 suppl):5-31.
5. American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions [published online ahead of print February 8, 2011]. J Am Acad Dermatol. 2011;65:137-174.
6. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol . 2005;53(1, suppl 1):S50-S58.
7. Menter A, Korman NJ, Elmets CA, et al; American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. section 3. guidelines of care for the management and treatment of psoriasis with topical therapies [published online ahead of print February 13, 2009]. J Am Acad Dermatol. 2009;60:643-659.
8. Koo J. New developments in topical sequential therapy for psoriasis. Skin Therapy Lett . 2005;10:1-4.
9. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev . 2009;2:CD005028.
10. Belge K, Brück J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep . 2014;6:4.
11. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs . 2014;74:423-441.
12. Boehncke WH, Qureshi A, Merola JF, et al. Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol. 2014;170:772-786.
13. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis . 2007;80(suppl 5):20-28.
14. Feldman SR, Gelfand JM, Stein Gold L, et al. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79(suppl 1[ii]):18-31.
15. Kircik L. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10:878-882.
16. Taclonex [product insert]. Parsippany, NJ: LEO Pharma Inc; 2014.
17. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217:107-113.
18. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomized, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20:465-471.
19. Menter A, Stein Gold L, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12:92-98.
20. Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59:455-463.
21. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol . 2009;160:170-176.
22. Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222:148-156.
23. Kragballe K, van de Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28:10-21.
24. Lebwohl MG, Corvari L. Compatibility of topical therapies for psoriasis: challenges and innovations. Cutis. 2007;79(suppl 1[ii]):5-10.
25. Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 1998;38(6, pt 1):1010-1011.
26. Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004;43:611-617.
27. Sandoval LF, Feldman SR. Topical corticosteroids. In: Koo JYM, Levin EC, Leon A, et al, eds. Moderate to Severe Psoriasis . 4th ed. Boca Raton, FL: CRC Press Taylor & Francis Group; 2014:21-36.
28. deShazo R, Krueger GG, Duffin KC. Topical agents. In: Koo JYM, Levin EC, Leon A, et al, eds. Moderate to Severe Psoriasis . 4th ed. Boca Raton, FL: CRC Press Taylor & Francis Group; 2014:41-65.
29. Hegyi Z, Zwicker S, Bureik D, et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132:1416-1424.
30. Lovato P, Norsgaard H, Ropke M. Key immunomodulatory effects exerted by calcipotriol in combination with corticosteroid on human cells. Poster presented at: 21st European Academy of Dermatology and Venereology Congress; September 27-30, 2012; Prague, Czech Republic.
31. Renton C. Diagnosis and treatment of adults with scalp psoriasis. Nurs Stand. 2014;28:35-39.
32. Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-224.
33. Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in adolescents with scalp psoriasis: an open, non-controlled, 8-week trial. Poster presented at: American Academy of Dermatology 72nd Annual Meeting; March 21-25, 2014; Denver, CO.
34. Ortonne JP, Tan J, Nordin P, et al. Quality of life of patients with scalp psoriasis treated with calcipotriene plus betamethasone dipropionate gel compared to calcipotriene solution. J Am Academy Dermatol . 2008;58(2, suppl 2):AB134.
35. Mrowietz U, Macheleidt O, Eicke C. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-gel): results [in German]. J Dtsch Dermatol Ges. 2011;9:825-831.
36. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217:321-328.
37. Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49:1328-1333.
38. Silver S, Tuppal R, Gupta AK, et al. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. J Drugs Dermatol. 2013;12:882-888.
